CoChat

Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression

Open access
Detka, Jan, Głombik, Katarzyna · 2021 · Pharmacological Reports

The DOI matches its Crossref record; 130 of the 130 references it cites were found in a registry or an index.

Abstract

Depression is a highly prevalent mood disorder and one of the major health concerns in modern society. Moreover, it is characterized by a high prevalence of coexistence with many other diseases including metabolic disorders such as type 2 diabetes mellitus (T2DM) and obesity. Currently used antidepressant drugs, which mostly target brain monoaminergic neurotransmission, have limited clinical efficacy. Although the etiology of depression has not been fully elucidated, current scientific data emphasize the role of neurotrophic factors deficiencies, disturbed homeostasis between the nervous system and the immune and endocrine systems, as well as disturbances in brain energy metabolism and dysfunctions in the gut-brain axis as important factors in the pathogenesis of this neuropsychiatric disorder. Therefore, therapeutic options that could work in a way other than classic antidepressants are being sought to increase the effectiveness of the treatment. Interestingly, glucagon-like peptide-1 receptor agonists (GLP-1RAs), used in the treatment of T2DM and obesity, are known to show pro-cognitive and neuroprotective properties, and exert modulatory effects on immune, endocrine and metabolic processes in the central nervous system. This review article discusses the potential antidepressant effects of GLP-1RAs, especially in the context of their action on the processes related to neuroprotection, inflammation, stress response, energy metabolism, gut-brain crosstalk and the stability of the gut microbiota. Graphic abstract

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s43440-021-00274-8

Cites

130 of 130 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 130 references

Cited by

See all 79

Metadata

Authors
Detka, J., & Głombik, K.
Affiliations
Maj Institute of Pharmacology (PL)
Corresponding author
Detka, Jan
Venue
Pharmacological Reports
Published
2021-05-18
Volume
73
Issue
4
Pages
1020-1032
ISSN
  • 1734-1140 (ISSN-L)
  • 2299-5684
OpenAlex
W3162613451
Cited by
79
References
130
Citations by year
2026: 10 · 2025: 34 · 2024: 16 · 2023: 10 · 2022: 8 · 2021: 1
FWCI
1.11
Type
journal article
Language
en
Open access
Licence
Locations
  • Pharmacological Reports (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Instytut Farmakologii, Polskiej Akademii Nauk (Statutory Funds)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
GLP-1 receptor agonists, depression, antidepressant effects, neuroprotection, neuroinflammation, stress response, brain energy metabolism, gut-brain axis, gut microbiota, type 2 diabetes, obesity, neurotrophic factors
MeSH terms
Neuroprotection, Gastrointestinal Microbiome, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Antidepressive Agents, Depression, Energy Metabolism, Humans, Inflammation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression. https://app.cochat.ai/papers/10.1007/s43440-021-00274-8
The paper
Detka, J., & Głombik, K. (2021). Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression. Pharmacological Reports. https://doi.org/10.1007/s43440-021-00274-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.